Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Work In Process (2023 - 2025)

Cytosorbents' Work In Process history spans 3 years, with the latest figure at $1.0 million for Q4 2025.

  • Quarterly results put Work In Process at $1.0 million for Q4 2025, up 101.59% from a year ago — trailing twelve months through Dec 2025 was $1.0 million (up 101.59% YoY), and the annual figure for FY2025 was $1.0 million, up 101.59%.
  • Work In Process for Q4 2025 was $1.0 million at Cytosorbents, down from $1.1 million in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $1.1 million in Q3 2025 to a low of $503000.0 in Q4 2024.
  • The 3-year median for Work In Process is $810435.5 (2023), against an average of $814904.5.
  • The sharpest move saw Work In Process crashed 40.04% in 2024, then surged 101.59% in 2025.
  • Year by year, Work In Process stood at $838871.0 in 2023, then crashed by 40.04% to $503000.0 in 2024, then soared by 101.59% to $1.0 million in 2025.
  • According to Business Quant data, Work In Process over the past three periods came in at $1.0 million, $1.1 million, and $782000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.